-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with the imitation of Class 3 Sodium Glucose Injection, which is the second domestic company
.
According to the first quarterly report of 2022, Kelun Pharmaceutical's net profit increased by 66.
08% year-on-year, and the half-year net profit is expected to increase by 35% to 55% year-on-year
.
$1.
5 Billion Big Variety! Sprint, the second domestic company, Sugammadex Glucose Sodium, is the world's first selective muscle relaxation antagonist approved for reversing neuromuscular blocking agents.
It can improve the state of muscle relaxation, promote the recovery of spontaneous breathing and limb mobility, and help improve the postoperative outcome of patients
.
Merck's Sugammadex Sodium Glucose Injection was first approved by the European Union in 2008, approved by the FDA in 2015, and approved to enter the Chinese market in 2017, with global sales reaching US$1.
532 billion in 2021
.
According to data from Minet.
com, in 2020, the sales of terminal Shugeng Sodium Glucose Injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 170 million yuan, a year-on-year increase of 140.
35%.
; In the first half of 2021, its sales have surpassed the full year of 2020, an increase of 226.
50% over the same period
.
Sales of Sugeng Glucose in Chinese Public Medical Institutions (Unit: 10,000 yuan) Source: Minet The company passed by with the first imitation
.
On April 12, 2022, Yangzijiang Pharmaceutical's Shugeng Sodium Glucose Injection was successfully approved for marketing, becoming the first domestic imitation
.
As the first company to apply for production, Kelun Pharmaceutical has recently changed the registration status of this product to "under approval".
If it is successfully approved, it will be regarded as a review and become the second domestic company
.
Net profit rose 66% in the first quarter! The net profit in the first half of the year is expected to increase by 35% to 55%.
Since April this year, Kelun Pharmaceutical has made a series of new progress in innovative research and development, and the performance report is also full of good news.
.
On April 10, Kelun Pharmaceutical released its 2021 annual report.
The company achieved operating income of 17.
277 billion yuan, a year-on-year increase of 4.
94%; net profit attributable to shareholders of the listed company was 1.
103 billion yuan, a year-on-year increase of 32.
94%
.
During the reporting period, the company made every effort to expand the market of infusion and non-infusion preparation products, and the operating income and profit increased year-on-year; the approved generic drugs in recent years continued to increase in volume, and the operating income and profit increased rapidly
.
On April 26, Kelun Pharmaceutical released its first quarterly report for 2022.
The company achieved an operating income of about 4.
482 billion yuan, a year-on-year increase of 7.
97%; the net profit attributable to shareholders of the listed company was about 291 million yuan, a year-on-year increase of 66.
09%
.
It is gratifying that Kelun Pharmaceuticals also announced a performance forecast.
It is expected that the net profit attributable to shareholders of listed companies from January to June 2022 will be 665 million to 764 million yuan, a year-on-year change of 35.
00% to 55.
00%
.
In this regard, Kelun Pharmaceutical stated: 1.
The price of the main products of its subsidiary Yili Chuanning Biotechnology Co.
, Ltd.
increased year-on-year, and the sales revenue and net profit increased year-on-year; 2.
The company made every effort to expand the market of core business products and continued to optimize the product structure.
, operating income and gross profit increased year-on-year; 3.
Generic drugs continued to increase in volume, operating income and gross profit increased year-on-year
.
Data source: Minet database, company announcement
.
According to the first quarterly report of 2022, Kelun Pharmaceutical's net profit increased by 66.
08% year-on-year, and the half-year net profit is expected to increase by 35% to 55% year-on-year
.
$1.
5 Billion Big Variety! Sprint, the second domestic company, Sugammadex Glucose Sodium, is the world's first selective muscle relaxation antagonist approved for reversing neuromuscular blocking agents.
It can improve the state of muscle relaxation, promote the recovery of spontaneous breathing and limb mobility, and help improve the postoperative outcome of patients
.
Merck's Sugammadex Sodium Glucose Injection was first approved by the European Union in 2008, approved by the FDA in 2015, and approved to enter the Chinese market in 2017, with global sales reaching US$1.
532 billion in 2021
.
According to data from Minet.
com, in 2020, the sales of terminal Shugeng Sodium Glucose Injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 170 million yuan, a year-on-year increase of 140.
35%.
; In the first half of 2021, its sales have surpassed the full year of 2020, an increase of 226.
50% over the same period
.
Sales of Sugeng Glucose in Chinese Public Medical Institutions (Unit: 10,000 yuan) Source: Minet The company passed by with the first imitation
.
On April 12, 2022, Yangzijiang Pharmaceutical's Shugeng Sodium Glucose Injection was successfully approved for marketing, becoming the first domestic imitation
.
As the first company to apply for production, Kelun Pharmaceutical has recently changed the registration status of this product to "under approval".
If it is successfully approved, it will be regarded as a review and become the second domestic company
.
Net profit rose 66% in the first quarter! The net profit in the first half of the year is expected to increase by 35% to 55%.
Since April this year, Kelun Pharmaceutical has made a series of new progress in innovative research and development, and the performance report is also full of good news.
.
On April 10, Kelun Pharmaceutical released its 2021 annual report.
The company achieved operating income of 17.
277 billion yuan, a year-on-year increase of 4.
94%; net profit attributable to shareholders of the listed company was 1.
103 billion yuan, a year-on-year increase of 32.
94%
.
During the reporting period, the company made every effort to expand the market of infusion and non-infusion preparation products, and the operating income and profit increased year-on-year; the approved generic drugs in recent years continued to increase in volume, and the operating income and profit increased rapidly
.
On April 26, Kelun Pharmaceutical released its first quarterly report for 2022.
The company achieved an operating income of about 4.
482 billion yuan, a year-on-year increase of 7.
97%; the net profit attributable to shareholders of the listed company was about 291 million yuan, a year-on-year increase of 66.
09%
.
It is gratifying that Kelun Pharmaceuticals also announced a performance forecast.
It is expected that the net profit attributable to shareholders of listed companies from January to June 2022 will be 665 million to 764 million yuan, a year-on-year change of 35.
00% to 55.
00%
.
In this regard, Kelun Pharmaceutical stated: 1.
The price of the main products of its subsidiary Yili Chuanning Biotechnology Co.
, Ltd.
increased year-on-year, and the sales revenue and net profit increased year-on-year; 2.
The company made every effort to expand the market of core business products and continued to optimize the product structure.
, operating income and gross profit increased year-on-year; 3.
Generic drugs continued to increase in volume, operating income and gross profit increased year-on-year
.
Data source: Minet database, company announcement
